AstraZeneca Reports Results of Calquence (acalabrutinib) in P-III ELEVATE TN

Shots: The P-III ELEVATE TN study involves assessing of Calquence + obinutuzumab / Calquence as monothx. vs chlorambucil + obinutuzumab in 535 patients in a ratio (1:1:1) with previously untreated CLL aged ≥65yrs. or b/w 18-65yrs. with CIRS> 6 or creatinine clearance of 30-69 mL/min Results: @24mos.patients remained free of disease progression or death (93%/ […]Read More